Highlight Therapeutics is a Spanish biotechnology company specialising in immuno-oncology, focused on the development of innovative cancer therapies. Its lead investigational compound, BO-112, is a do...
Highlight Therapeutics and CNIO are collaborating to proof BO-112 effectiveness against the most common form of skin cancer, which is linked to sun exposure and is on the rise.
Highlight Therapeutics,(“Highlight”), una compañía biofarmacéutica clínica que desarrolla tratamientos antitumorales basados en RNA, y Pivotal, una CRO de implantación Europea y que ofrece se...
Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, and Pivotal, a Europe-wide full-service CRO, today announced tha...